Phase 1 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with colorectal cancer (cancer of the colon or rectum) that has spread to other parts of the body and cannot be removed by surgery, confirmed by laboratory testing of tissue.
- People whose tumor has been tested and does not have a specific genetic feature called "MSI-H" (meaning the tumor's DNA repair system is working normally).
- People whose cancer can be measured on scans using standard medical criteria.
- People whose cancer has come back or continued to grow after receiving at least one previous treatment for advanced disease, which must have included a chemotherapy regimen called FOLFOX.
- People who are due to receive FOLFOX chemotherapy as their next treatment.
- People who have little to no lasting nerve damage (such as numbness or tingling) from previous chemotherapy.
- People who are generally well enough to carry out light activity and care for themselves (based on a standard fitness scale used in cancer trials).
- People with adequately functioning organs, including the liver, kidneys, lungs, and heart.
- People who are able to provide a tumor tissue sample at the start of the trial (screening biopsy).
Who may not be able to join:
- People who have taken part in another clinical trial or used an experimental treatment or device within the 4 weeks before starting the study.
- People who have received any anti-cancer treatment within the 4 weeks before starting the study.
- People who have been given a white blood cell boosting medication (such as filgrastim/G-CSF) within 7 days before starting the study.
- People who have previously been treated with a type of immunotherapy that targets certain immune checkpoint proteins (such as anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or similar immune-targeting therapies).
- People who have had radiation therapy within 2 weeks before the planned start of the study treatment.
- People who have had major surgery within 4 weeks before the planned start of the study treatment.
- People who have received a live vaccine within 30 days before the planned start of the study treatment.
- People with a serious or uncontrolled illness or medical condition.
- People who have a history of lung inflammation (pneumonitis) that required steroid treatment, or who currently have lung inflammation shown on recent chest imaging.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +3210394100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The Occurrence of Dose Limiting Toxicities (DLT) during the 'DLT reporting period'; The objective response rate (ORR) at the tumor assessment on Day 94 [Visit 15])
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.